Resources from the same session
1646MO - Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma
Presenter: Christine Dierks
Session: Mini Oral session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1647MO - BRAF mutated anaplastic thyroid carcinoma: Clinical characteristics and outcome under BRAF inhibitors and chemotherapy in real-life practice, a multicentric retrospective study of the French ENDOCAN TUTHYREF network
Presenter: Christelle de la Fouchardiere
Session: Mini Oral session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
888MO - Emergence of clonal hematopoiesis after peptide receptor radionuclide therapy for neuroendocrine tumors
Presenter: Rachel El Ferkh
Session: Mini Oral session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
889MO - Comparative expression of driver transcription factors in extra-pulmonary small cell carcinoma
Presenter: Stephen Liu
Session: Mini Oral session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
890MO - Mutation spectrum in liquid versus solid biopsies from advanced digestive neuroendocrine carcinoma patients
Presenter: Halfdan Sorbye
Session: Mini Oral session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
496MO - Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin
Presenter: Rocio Garcia-Carbonero
Session: Mini Oral session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
LBA46 - Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study
Presenter: Thomas Walter
Session: Mini Oral session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 888MO, 889MO, 890MO, 496MO and LBA46
Presenter: Mauro Cives
Session: Mini Oral session: NETs and endocrine tumours
Resources:
Slides
Webcast
1MO - An open-label, phase II trial of cabozantinib for advanced adrenocortical carcinoma
Presenter: Matthew Campbell
Session: Mini Oral session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
2MO - EO2401 (EO) therapeutic vaccine for patients (pts) with adrenocortical carcinoma (ACC) and malignant pheochromocytoma/paraganglioma (MPP): Phase I/II SPENCER study
Presenter: Eric Baudin
Session: Mini Oral session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast